Clinical Trial Results: A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 trial results for CVL-231 (Emraclidine) in adults with schizophrenia have been completed with results posted. The study evaluated safety and tolerabilit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• CVL-231 (Emraclidine) (emraclidine)

Snippet

Sponsor: AbbVie | Conditions: Schizophrenia | Phase 2 | Status: TERMINATED | Results posted: 2026-08-21